# Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)

> **NCT04574830** · — · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 18 (actual)

## Conditions studied

- Glycogen Storage Disease Type III

## Interventions

- **OTHER:** No Intervention

## Key facts

- **NCT ID:** NCT04574830
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-23
- **Primary completion:** 2022-06-30
- **Final completion:** 2022-06-30
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2022-09-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04574830

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04574830, "Study to Evaluate Biomarkers and Clinical Manifestations in Individuals With Glycogen Storage Disease Type III (GSD III)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT04574830. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*